1. Home
  2. FT vs CDXS Comparison

FT vs CDXS Comparison

Compare FT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

SELL

Current Price

$7.42

Market Cap

178.7M

Sector

Finance

ML Signal

SELL

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.08

Market Cap

154.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
CDXS
Founded
1988
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Major Chemicals
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
178.7M
154.4M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FT
CDXS
Price
$7.42
$1.08
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.14
AVG Volume (30 Days)
56.8K
★ 843.0K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 7.85%
N/A
EPS Growth
N/A
★ 43.82
EPS
★ N/A
N/A
Revenue
N/A
★ $138,590,000.00
Revenue This Year
N/A
$4.97
Revenue Next Year
N/A
$18.69
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 32.30
52 Week Low
$6.95
$0.96
52 Week High
$8.35
$2.98

Technical Indicators

Market Signals
Indicator
FT
CDXS
Relative Strength Index (RSI) 63.19 33.44
Support Level $6.95 $0.96
Resistance Level $8.32 $1.24
Average True Range (ATR) 0.09 0.09
MACD 0.04 -0.02
Stochastic Oscillator 94.12 12.50

Price Performance

Historical Comparison
FT
CDXS

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: